Comments
Zydus Cadila on Tuesday said it has received the US health regulator’s approval to market aripiprazole orally disintegrating tablets, used in treating schizophrenia, in the American market.
The company has received a tentative approval from the US Food and Drug Administration for aripiprazole orally disintegrating tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg, Zydus Cadila said in a statement.
The drug is an anti-psychotic medication used in the treatment of schizophrenia. Shares of Zydus group’s listed entity Cadila Healthcare today closed at Rs 877.10 apiece on the BSE, up 0.82 per cent from its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.